Editorial Standards, Methodology & Conflict of Interest Policy

How we research, score, update, and correct provider information — and how we handle conflicts of interest.

1. Sources we use, in order of priority

1. FDA (drug approvals, warning letters, prescribing labels, compounding guidance)
2. Peer-reviewed clinical trials (NEJM, JAMA, Lancet) for efficacy and safety claims
3. Provider-published documentation (pricing pages, terms of service, prescribing protocols)
4. Pharmacy accreditation databases (NABP, state boards of pharmacy, LegitScript)
5. Third-party consumer review platforms (Trustpilot, BBB, app store ratings) — used only as a directional signal, with the date of review noted
6. State telehealth and prescribing rule databases for availability claims

2. Ranking methodology

Each provider in the comparison is assessed across these categories:

• Pricing transparency & structure — published rates, dose escalation behaviour, contract length, included support
• Medication sourcing — pharmacy licensing, accreditation, FDA-approved vs compounded, third-party potency/sterility testing where the provider performs it
• Clinician oversight — provider-led care model, clinician credentials, follow-up cadence (note: model varies by state and provider; we describe rather than rank)
• Patient support & programs — included nutrition/fitness/behavioural support, app experience, accessibility
• Patient-reported experience — third-party review aggregates with the date of review noted

We do not use a numeric weighted-score formula because pricing structures, eligibility rules, and clinical models are too heterogeneous across providers to fairly reduce to a single number. Categories are described qualitatively, with hard data (pricing, dose, accreditation status) cited from public sources.

3. Pricing claims

Pricing shown on this site is reviewed against each provider's publicly available pricing pages on the date noted. Pricing may vary by state, plan length, eligibility, medication, and availability. Where a quoted rate (e.g., NexLife $186/mo) is the lowest tier of a multi-month commitment plan, we say so explicitly and show the month-to-month rate alongside it.

4. Medical claims

Clinical-outcome figures (e.g., 22.5% weight loss at 72 weeks for tirzepatide 15mg) come from the SURMOUNT and STEP trial programs of FDA-approved branded medication. These outcomes are from clinical trials of FDA-approved products and should not be interpreted as expected results from any specific telehealth program — compounded or otherwise. All clinical claims are cited to PubMed and primary publications.

Clinical content on this site is medically reviewed by Adam Kennah, M.D., who also serves as Medical Director at NexLife Inc. Readers requiring fully independent medical review should consult their own licensed clinician.

5. Update cadence

The provider directory and pricing data are reviewed monthly. The comparison and rankings are reviewed at minimum quarterly, and immediately when an FDA action, large pricing change, or material program change occurs at any reviewed provider. Each page shows the "last reviewed" date.

6. Conflict of interest policy

• Ownership relationship. The site is operated by people affiliated with NexLife Inc. This is disclosed at the top of every page.
• Affiliate / referral links. Outbound provider buttons (NexLife, Hims, Calibrate, Noom, Ro, Sequence, Mochi, Henry Meds, etc.) are affiliate or referral links and use tracking parameters. We may earn a referral fee when a reader signs up via these links.
• Provider compensation. Reviewed providers do not pay to be ranked, do not preview or approve our copy before publication, and do not have editorial control. Some providers (including NexLife) may have a referral relationship with us as described above.
• Advertising. The site does not currently sell paid display advertising or sponsored ranking slots. If this changes, the policy will be updated and disclosed.
• Editorial review process. Drafts are reviewed by the editorial researcher (Sadaf Najafi) and, for clinical claims, by Dr. Kennah. Readers may request a correction at any time.

7. Correction policy

If you believe any factual claim on this site — including a competitor pricing, accreditation, or clinical claim — is inaccurate, please email [email protected] with the URL, the claim in question, and the source you believe is correct. We aim to review within 5 business days. Material corrections are dated and disclosed inline on the page.

8. What we are not

TirzepatideReview.com is not a healthcare provider, pharmacy, insurance broker, or licensed medical practice. We do not prescribe, dispense, or provide medical advice. Treatment is not guaranteed. Eligibility is determined by a licensed clinician at the chosen provider after intake review.

Last reviewed

This page was last reviewed: April 28, 2026.